Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 302

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock

Open access
Alejandria, Marissa M, Lansang, Mary Ann D, Dans, Leonila F, Mantaring III, Jacinto Blas·2013·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010. OBJECTIVES: To estimate the effects of IVIG as adjunctive therapy in patients with bacterial sepsis or septic shock on mortality, bacteriological failure rates, and duration of stay in hospital. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 6), MEDLINE (1966 to December 2012), and EMBASE (1988 to December 2012). We contacted investigators in the field for unpublished data. The original search was performed in 1999 and updated in 2002 and 2008. SELECTION CRITERIA: We included randomized controlled trials comparing IVIG (monoclonal or polyclonal) with placebo or no intervention in patients of any age with bacterial sepsis or septic shock. DATA COLLECTION AND ANALYSIS: Two authors independently assessed the studies for inclusion and undertook methodologic quality assessment and data abstraction. We conducted pre-specified subgroup analyses by type of immunoglobulin preparation. MAIN RESULTS: We included 43 studies that met our inclusion criteria in this updated review out of 88 potentially eligible studies. The studies included a large polyclonal IVIG trial in neonates that was concluded in 2011 and classified as ongoing in the 2010 version of this review. Pooled analysis of polyclonal and monoclonal IVIG was not done due to clinical heterogeneity. Subgroup analysis of 10 polyclonal IVIG trials (n = 1430) and seven trials on IgM-enriched polyclonal IVIG (n = 528) showed significant reductions in mortality in adults with sepsis compared to placebo or no intervention (relative risk (RR) 0.81; 95% confidence interval (CI) 0.70 to 0.93 and RR 0.66; 95% CI 0.51 to 0.85, respectively). Subgroup analysis of polyclonal IVIG in neonates, which now includes the recently concluded large polyclonal IVIG trial, showed no significant reduction in mortality for standard IVIG (RR 1.00; 95% CI 0.92 to 1.08; five trials, n = 3667) and IgM-enriched polyclonal IVIG (RR 0.57; 95% CI 0.31 to 1.04; three trials, n = 164). Sensitivity analysis of trials with low risk of bias showed no reduction in mortality with polyclonal IVIG in adults (RR 0.97; 95% CI 0.81 to 1.15; five trials, n = 945) and neonates (RR 1.01; 95% CI 0.93 to 1.09; three trials, n = 3561). Mortality was not reduced among patients (eight trials, n = 4671) who received anti-endotoxin antibodies (RR 0.99; 95% CI 0.91 to1.06) while anti-cytokines (nine trials, n = 7893) demonstrated a marginal reduction in mortality (RR 0.92; 95% CI 0.86 to 0.97). AUTHORS' CONCLUSIONS: Polyclonal IVIG reduced mortality among adults with sepsis but this benefit was not seen in trials with low risk of bias. Among neonates with sepsis, there is sufficient evidence that standard polyclonal IVIG, as adjunctive therapy, does not reduce mortality based on the inclusion of the large polyclonal IVIG trial on neonates. For Ig-M enriched IVIG, the trials on neonates and adults were small and the totality of the evidence is still insufficient to support a robust conclusion of benefit. Adjunctive therapy with monoclonal IVIGs remains experimental.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001090.pub2

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Research works printed but not linked: 49

  1. Behre, 1995, Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial, Antiinfective Drugs and Chemotherapy, 13, 129
  2. The INIS Study Collaborative Group, 2008, The INIS Study. International Neonatal Immunotherapy Study: Non-specific intravenous immunoglobulin therapy for suspected or proven neonatal sepsis: an international, placebo-controlled, multicentre randomised trial, BMC Pregnancy and Childbirth, 8, 1, 10.1186/1471-2393-8-52 · doi:10.1186/1471-2393-8-52
  3. Chen, 1996, Intravenous immunoglobulin in the treatment of full term and premature newborns with sepsis, Journal of the Formosan Medical Association: Taiwan Yi Zhi, 11, 839
  4. Simone, 1988, Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients, Critical Care Medicine, 16, 23, 10.1097/00003246-198801000-00005 · doi:10.1097/00003246-198801000-00005
  5. Dominioni, 1996, High-dose intravenous IgG for treatment of severe surgical infections, Digestive Surgery, 13, 430, 10.1159/000172479 · doi:10.1159/000172479
  6. Erdem, 1993, The use of IgM-enriched intravenous immunoglobulin for the treatment of neonatal sepsis in preterm infants, The Turkish Journal of Pediatrics, 35, 277
  7. Haque, 1988, IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis, American Journal of Diseases of Childhood, 142, 1293
  8. Lindquist, 1981, Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicemia and pneumonia, Vox Sanguinis, 40, 329
  9. Mancilla-Ramírez, 1992, Intravenous immunoglobulin in the treatment of neonatal septicemia, Boletín Médico del Hospital Infantil de México, 49, 4
  10. Masaoka, 2000, The efficacy of intravenous immunoglobulin in combination therapy with antibiotics for severe infections, Japanese Journal of Chemotherapy, 48, 199
  11. Samatha, 1997, Role of IgM-enriched intravenous immunoglobulin as an adjuvant to antibiotics in neonatal sepsis, Karnataka Pediatric Journal, 11, 1
  12. Yakut, 1998, Effects of immunoglobulin G on surgical sepsis and septic shock, Bulletin of Gulhane Military Medical Academy, 40, 76
  13. Aitchison, 1985, Anti-endotoxin in the treatment of surgical septic shock. Results of a randomized double-blind trial, South African Medical Journal, 68, 787
  14. Bojic, 1998, The significance of immunoglobulins in the treatment of patients with sepsis and septic shock, Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review, 55 (2 Suppl), 75
  15. Fischer, 1983, Functional antibacterial activity of a human intravenous immunoglobulin preparation: in vitro and in vivo studies, Vox Sanguinis, 44, 296, 10.1111/j.1423-0410.1983.tb04485.x · doi:10.1111/j.1423-0410.1983.tb04485.x
  16. Freeman, 1999, The role of inflammation in sepsis and septic shock: a meta-analysis of both clinical and pre-clinical trials of anti-inflammatory therapies, 965
  17. Gökalp, 1994, Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates, Clinical Pediatrics, 33, 349, 10.1177/000992289403300607 · doi:10.1177/000992289403300607
  18. Gunes, 2006, Exchange transfusion or intravenous immunoglobulin therapy as an adjunct to antibiotics for neonatal sepsis in developing countries: a pilot study, Annals of Tropical Paediatrics, 26, 39, 10.1179/146532806X90592 · doi:10.1179/146532806x90592
  19. Haque, 1995, Comparison of two types of intravenous immunoglobulins in the treatment of neonatal sepsis, Clinical and Experimental Immunology, 101, 328, 10.1111/j.1365-2249.1995.tb08359.x · doi:10.1111/j.1365-2249.1995.tb08359.x
  20. Homan, 1990, Safety of intravenous immunoglobulin in neonates at risk for sepsis, American Journal of Perinatology, 7, 267, 10.1055/s-2007-999510 · doi:10.1055/s-2007-999510
  21. Jaspers, 1987, Antibody to lipid A in the treatment of septic shock, Infection, 15 Suppl 2, 89, 10.1007/BF01644200 · doi:10.1007/bf01644200
  22. Jesdinsky, 1987, Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis, Klinische Wochenschrift, 65, 1132, 10.1007/BF01734833 · doi:10.1007/bf01734833
  23. Jones, 1995, Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial, Burns, 21, 267, 10.1016/0305-4179(94)00004-H · doi:10.1016/0305-4179(94)00004-h
  24. Kay CA Can better measures of cytokine responses be obtained to guide cytokine inhibition? Knoll AG, Ludwigshafen, Germany. Presentation and handout. Cambridge Health Institutes' Designing Better Drugs and Trials for Sepsis/SIRS: Reducing mortality to patients and suppliers
  25. Kett, 1994, An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody, Critical Care Medicine, 22, 1227, 10.1097/00003246-199408000-00005 · doi:10.1097/00003246-199408000-00005
  26. Kornelisse, 1997, Meningococcal septic shock in children: clinical and laboratory features, outcome and development of a prognostic score, Clinical Infectious Diseases, 25, 640, 10.1086/513759 · doi:10.1086/513759
  27. Marenovic, 1998, High doses of immunoglobulins decrease mortality rate of surgical patients with severe intraabdominal infections and sepsis, Vojnosanitetski Pregled. Military-medical and Pharmaceutical Review, 55 (2 Suppl), 71
  28. Okamoto, 1985, Clinical studies on the effectiveness of SM-4300, a new non-modified gamma globulin preparation suitable for intravenous use, in refractory infections, The Japanese Journal of Antibiotics, 38, 2515
  29. Panko, 1976, Use of staphylococcal plasma and antistaphylococcal immunoglobulin in treatment of staphylococcal sepsis, Khirurgiia, 9, 95
  30. Pilz, 1997, Comparison of early IgM-enriched immunoglobulin vs. polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis, Chest, 111, 419, 10.1378/chest.111.2.419 · doi:10.1378/chest.111.2.419
  31. Schedel, 1996, [Therapy of gram-negative septicotoxic diseases with pentaglobin - immunoglobulin with increased IgM content: a prospective randomized clinical study], Anesteziologiia i Reanimatologiia, 199, 4
  32. Sidiropolous, 1981, Immunoglobulin substitution in the treatment of neonatal septicemia, Schweizerische Medizinische Wochenschrift, 111, 1649
  33. Tomii, 1985, Clinical study of SM-4300 in the field of medicine, The Japanese Journal of Antibiotics, 38, 2503
  34. Ueda, 1985, A clinical trial of SM-4300 against severe infections in surgery, The Japanese Journal of Antibiotics, 38, 2647
  35. Wang, 2006, Treatment of septic thrombocytopenia with immunoglobulin, Chinese Journal of Emergency Medicine, 15, 905
  36. Yildizidas, 2005, Does polyclonal intravenous immunoglobulin reduce mortality in septic children in pediatric intensive care unit?, Cocuk Sagligi Ve Hastaliklari Dergisi, 48, 136
  37. Alejandria, 2000, Epidemiology and predictors of mortality from sepsis in medical patients at UP-PGH, Philippine Journal of Microbiology and Infectious Diseases, 29, 23
  38. Dahlberg, 1997, Endotoxins and sepsis, 45
  39. Higgins, [updated March 2011], Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
  40. Norrby-Teglund, 2003, Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections, Scandinavian Journal of Infectious Diseases, 35, 683, 10.1080/00365540310015944 · doi:10.1080/00365540310015944
  41. Nydegger, 1997, Sepsis and polyspecific intravenous immunoglobulins, Journal of Clinical Apheresis, 12, 93, 10.1002/(SICI)1098-1101(1997)12:2<93::AID-JCA7>3.0.CO;2-4 · doi:10.1002/(sici)1098-1101(1997)12:2<93::aid-jca7>3.0.co;2-4
  42. Rangel-Frausto, 1995, The natural history of the systemic inflammatory response syndrome (SIRS), JAMA, 274, 968, 10.1001/jama.1995.03530020045022 · doi:10.1001/jama.1995.03530020045022
  43. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012
  44. Taguiang-Abu, 2008, Clinical determinants of outcome of severe sepsis among adult patients at the Philippine General Hospital Intensive Care Units, Philippine Journal of Internal Medicine, 46, 103
  45. Villa, 1995, Sepsis profile among patients in a tertiary care hospital, St Luke's Medical Journal, 2, 45
  46. Werdan K Pilz G the SBITs Study Group Polyvalent immune globulins [Abstract 18] Shock 1997 1918 · doi:10.1097/00024382-199703001-00020
  47. Werdan, 2001, Pathophysiology of septic shock and multiorgan dysfunction syndrome and various therapeutic approaches with special emphasis on immunoglobulins, Therapeutic Apheresis, 5, 115, 10.1046/j.1526-0968.2001.005002115.x · doi:10.1046/j.1526-0968.2001.005002115.x
  48. Wortel, 1993, Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective randomized clinical trial (Letter to the Editor), Critical Care Medicine, 21, 163, 10.1097/00003246-199301000-00042 · doi:10.1097/00003246-199301000-00042
  49. Zabala MLB Dans LF Prescribing patterns for immunoglobulin use among pediatricians in 3 Metro Manila hospitals Conference Proceedings 2nd World Congress of Pediatric Infectious Diseases

Cited by

See all 302

Metadata

Authors
Alejandria, M. M., Lansang, M. A. D., Dans, L. F., & Mantaring III, J. B.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2013-09-16
Volume
2018
Issue
12
Pages
CD001090-CD001090
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1498847688
Cited by
302
References
80
FWCI
17.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. https://app.cochat.ai/papers/10.1002/14651858.cd001090.pub2
The paper
Alejandria, M. M., Lansang, M. A. D., Dans, L. F., & Mantaring III, J. B. (2013). Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001090.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.